Ashley Locklear-Batton, DO
Family Medicine · Myrtle Beach, SCNPI 1366882722
Payments from drug & device makers
Across 287 payments — averaging $14.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$757
- Novo Nordisk$628
- GSK$452
- Pfizer$280
- Amgen$225
- Johnson & Johnson$201
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,287100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $757 |
| Novo Nordisk | 31 | $628 |
| GSK | 27 | $452 |
| Pfizer | 23 | $280 |
| Amgen | 16 | $225 |
| Johnson & Johnson | 14 | $201 |
| Amarin Pharma, Inc. | 12 | $192 |
| AstraZeneca | 12 | $170 |
| Sumitomo Pharma America, Inc. | 5 | $131 |
| Abbott | 6 | $106 |
| Lilly USA, LLC | 7 | $97 |
| Merck | 6 | $85 |
| Upsher-smith Laboratories LLC | 4 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Sanofi-aventis U.S. LLC | 4 | $63 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Boston Scientific | 3 | $57 |
| Novartis | 4 | $54 |
| Nevro Corp. | 3 | $52 |
| Exact Sciences | 3 | $49 |
| Astellas Pharma US Inc | 3 | $45 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Sunovion Pharmaceuticals Inc. | 2 | $39 |
| Harmony Biosciences LLC | 2 | $39 |
| Dexcom, Inc. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Antares Pharma, Inc. | 2 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $24 |
| Scynexis, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Medtronic | 1 | $15 |
| Bausch Health US, LLC | 1 | $15 |
| Vital Connect, Inc | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Almatica Pharma LLC | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 3 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Bayer | 1 | $12 |
How this compares
$4,287 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $199,686 |
| MounjaroTirzepatide | 70 | $112,127 |
| RybelsusSemaglutide | 48 | $76,418 |
| JardianceEmpagliflozin | 46 | $72,851 |
| EliquisApixaban | 56 | $62,524 |
| JanuviaSitagliptin Phosphate | 27 | $43,657 |
| ProliaDenosumab | 21 | $36,068 |
| MyrbetriqMirabegron | 34 | $31,019 |
| FarxigaDapagliflozin Propanediol | 22 | $28,405 |
| LinzessLinaclotide | 24 | $25,297 |
| ViberziEluxadoline | 13 | $20,841 |
| XareltoRivaroxaban | 13 | $19,576 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $19,539 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $16,336 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $628 | $276,104172 claims |
| Lilly USA, LLCMounjaro | $97 | $112,12770 claims |
| Boehringer IngelheimJardiance | $14 | $72,85146 claims |
| PfizerEliquis, Paxlovid | $280 | $65,40872 claims |
| AbbVieLinzess, Viberzi, Savella, Synthroid | $757 | $54,951117 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $170 | $44,74148 claims |
| MerckJanuvia | $85 | $43,65727 claims |
| AmgenProlia | $225 | $36,06821 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $452 | $32,32837 claims |
| Astellas Pharma US IncMyrbetriq | $45 | $31,01934 claims |
| Johnson & JohnsonXarelto | $201 | $19,57613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Myrtle Beach
- Chad HubertyMyrtle Beach$575K
- Jonathan BornfreundMyrtle Beach$222K
- David WeitzmanMyrtle Beach$181K
- Patrick RyanMyrtle Beach$167K
- Edward McCarthyMyrtle Beach$86K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.